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Abstract
Trillions of microorganisms with a complex and diverse community are in the 
human gastrointestinal tract. Gut microbial genomes have much more genes than 
human genome, thus having a variety of enzymes for many metabolic activities; 
therefore, gut microbiota is recognized as an “organ” that has essential functions to 
human health. There are interactions between host and gut microbiome, and there 
are correlations between gut microbiome in the healthy state and in certain disease 
states, such as cancer, liver diseases, diabetes, and obesity. Gut microbiota can 
produce metabolites from nutrients of dietary sources and from drug metabolisms; 
these metabolites, for example, short-chain fatty acids (SCFAs), have substantial 
effects on human health. Drug-microbiome interactions play a crucial role in thera-
peutic efficiency. Some drugs are able to change compositions of gut microbiota, 
which can lead to either enhance or reduce therapeutic efficiency. This chapter 
provides an overview of roles of gut microbiota in human health and diseases and 
recent research studies on the metabolism or toxicity of drugs and natural products. 
Since gut bacteria considerably contribute to drug metabolism, research on the 
influence of gut microbiome on drug candidates (or natural products) should be 
part of the drug development processes.
Keywords: gut microbiota, gut microbiome, drug-microbiome interactions,  
drug-microbiota interactions, natural products-microbiome interactions,  
drug metabolism, drug toxicity, biotransformation, bioconversion
1. Introduction
The human gastrointestinal tract has various microorganisms, and “gut micro-
biota” has received attentions recently because the microbe population living in 
human intestine has significant effects to human health. Gut microbiota plays 
important roles in human, involving in many activities in a host body, for example, 
metabolism of xenobiotic compounds, immune system, nutrition, inflammation, 
and behavior. The delivery of prebiotics and probiotics to the human gastrointesti-
nal tract, via dietary products or supplements, is one of the tools for management 
of microbiota in order to improve host health [1]. Moreover, gut microbiome has 
interactions with drugs and natural products, producing metabolites, which give 
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effects on efficacy, metabolism, and toxicity of drugs. Gut microbiota plays a role 
in the metabolism of drugs and natural products, as well as nutrients in diet or 
food. The conversion of a dietary soybean isoflavone, daidzein (1) or genistein 
(2), to a bioactive compound, S-equol (3) (Figure 1) [2, 3], is a good example 
for the role of gut bacteria in the production of pharmacologically active agent in 
human because S-equol (3) is a potent ligand for estrogen receptor β [4]. Daidzein 
(1) is also derived from its corresponding isoflavone glycoside, daidzin (4), by 
Bifidobacterium, a representative of major bacterial species of human origin; 
this bacterium could transform daidzin (4) to daidzein (1) by cell-associated 
β-glucosidases (Figure 1) [5]. Moreover, O-desmethylangolensin (5) is also found as 
an intestinal bacterial metabolite of daidzein (1) [6, 7].
The transformation of achiral molecule daidzein (1) to a chiral molecule equol, 
which has one chiral center in its molecule, should provide two possible enantio-
mers of S-equol (3) and R-equol (3R) (Figure 2). However, gut bacteria selectively 
gives only S-equol (3), not R-equol (3R); this is interesting because only S-equol (3) 
has a high affinity to bind with estrogen receptor β, while R-equol (3R) has much 
less activity [4]. Therefore, S-equol (3), but not R-equol (3R), has high affinity for 
estrogen receptor β in human, and S-equol (3) has more potent estrogenic activity 
than estradiol [4]. In animal model, although a mixture of the two enantiomers of 
equol have the ability to inhibit bone loss in ovariectomized mice [8], S-equol (3) 
has better inhibitory effects on bone fragility than the racemic mixture containing 
both S-equol (3) and R-equol (3R) [9].
The ability of gut bacteria to selectively produce the correct bioactive isomer 
of S-equol (3) needed for human is intriguing. Shimada and co-workers identified 
enzymes involved in the bioconversion of daidzein (1) to S-equol (3) by the bacte-
rium Lactococcus sp. strain 20–92, which was isolated from feces of healthy human 
[10]. The enzyme daidzein reductase catalyzes the transformation of daidzein (1) 
to (R)-dihydrodaidzein (6), which is in turn converted to (S)-dihydrodaidzein (7) 
by the enzyme dihydrodaidzein racemase (Figure 2). The enzyme dihydrodaidzein 
reductase catalyzes the conversion of (S)-dihydrodaidzein (7) to trans-tetrahydro-
daidzein (8), which is converted to S-equol (3) by the enzyme tetrahydrodaidzein 
reductase [10]. The bioconversion of daidzein (1) selectively to S-equol (3), not 
R-equol (3R), by gut bacteria provides human the correct enantiomer for binding 
with estrogen receptor β; this may be host-bacterial mutualism in human intestine. 
An isoflavone daidzein (1) is found in leguminous plants such as soybeans and other 
Figure 1. 
Bioconversion of soybean isoflavones, daidzein (1), genistein (2), and daidzin (4), to S-equol (3) and 
O-desmethylangolensin (5) by intestinal bacteria.
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legumes, which have been used as food for human since ancient times. Therefore, 
it is possible that gut bacteria have experienced with daidzein (1) long time ago, 
and their enzymatic evolutions lead to the selective bioconversion of daidzein (1) 
to S-equol (3), which has biological activity for human. Interestingly, many studies 
revealed that there is the intestinal microbiota-to-host relationship, i.e., a cross talk, 
between gut microbiota and human host and interactions between gene products 
from the microbiome with metabolic systems of human diseases such as obesity and 
diabetes [11].
The conversion of a dietary soybean isoflavone, daidzein (1) or genistein (2), 
to S-equol (3), by gut bacteria has been known for many years; however, scientists 
might not be aware of the importance of gut microorganisms in the past. Recently, 
a number of studies have revealed many essential roles of gut microbiota in human 
health and diseases. Gut microbiome can transform nutrients and dietary fibers to 
produce bioactive metabolites, for example, short-chain fatty acids (SCFAs) and 
nicotinamide, which have a significant impact on human health and diseases. There 
have been reports on interactions of gut microbiome and compounds, e.g., drugs 
and natural products, after humans take these compounds as drugs for the treat-
ment of diseases. The metabolites obtained from the metabolism of drugs/natural 
products by the activities of gut microbiome have either positive or negative effects 
on therapeutic efficiency. This chapter provides the information of recent studies 
on the influence of the metabolites produced by gut microbiome on human health 
and diseases and on the interactions of microbiome and drugs/natural products.
2.  Contributions of metabolites produced by gut microbiome to human 
health and diseases
The human gastrointestinal tract has trillions of microorganisms with a complex 
and diverse community. Gut microbiome is recognized as an “organ” because gut 
Figure 2. 
Structures of two enantiomers of S-equol (3) and R-equol (3R) and the bioconversion of daidzein (1) to 
S-equol (3) by the bacterium Lactococcus sp. through the metabolites (R)-dihydrodaidzein (6),  
(S)-dihydrodaidzein (7), and trans-tetrahydrodaidzein (8).
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microorganisms have metabolic activities similar to an organ and have several 
essential functions to human health [12]. It is estimated that microbial cells in the 
human body are 10 times more than human cells and that gut microbiome has 
150 times more genes than human genome [13]. Perturbation of gut microbial 
communities leads to the imbalance of gut microorganisms, by either reducing or 
increasing particular microbial species or altering the relative abundance of certain 
microorganisms; this is collectively known as “dysbiosis.” Microbial dysbiosis can 
cause certain diseases such as irritable bowel syndrome, diabetes, cancer, inflamma-
tory bowel diseases, and obesity [14–16]. Gut microorganisms are able to produce 
many metabolites, which give substantial contributions to human health because 
they are involved in various physiological processes, i.e., host immunity, cell-to-cell 
communication, and energy metabolism [17, 18]. The metabolites produced by gut 
microbiome are linked with human diseases, for example, colorectal cancer [19], 
depression [20], inflammation and cancer [21], and cardiovascular and metabolic 
diseases [22, 23]. Among the metabolites produced by gut microbiome, SCFAs 
considerably play critical roles in human health. Gut microbiome produces acetate 
(9), propionate (10), and butyrate (11) (Figure 3), the respective conjugate bases 
of acetic acid, propionic acid, and butyric acid; these SCFAs are from saccharolytic 
fermentation of dietary fibers by gut microorganisms [24]. Butyrate (11) from the 
metabolism of gut microbiome could induce differentiation of colonic regulatory 
T cells in mice, suggesting that gut microorganisms are substantially involved in 
immunological homeostasis in the gastrointestinal tract of human [25]. SCFAs 
produced by gut microbiota are significantly linked with hypertension and kidney 
diseases [26]. SCFAs are vital fuels for intestinal epithelial cells and can maintain 
intestinal homeostasis; they are involved in the regulation of gut epithelial cells 
and immunity that is relevant to inflammatory bowel diseases [27, 28]. SCFAs 
are able to activate G-protein-coupled receptor, for example, GPR43, which has a 
role in intestinal inflammatory diseases, i.e., inflammatory bowel diseases [29]. 
Moreover, SCFAs produced by gut microbiome are energy source for colonocytes 
and can inhibit histone deacetylases, the enzymes catalyzing the removal of acetyl 
groups from the lysine residue of histone [30]. Recent study revealed that butyrate 
(11) from the metabolism of gut microbiome could promote histone crotonylation 
in colon epithelial cells and that the reduction of the gut microbiota leads to many 
changes in histone crotonylation in the colon [31].
Recent study revealed that SCFAs produced by gut microbiome had relation-
ships with metabolic diseases [32]. The level increase of butyrate (11) (Figure 3) by 
gut microbiome can improve insulin response after an oral glucose tolerance test; 
moreover, the defects in the production or absorption of propionate (10) led to an 
increased risk of type 2 diabetes [32]. Previous study also demonstrated that type 2 
diabetes is linked with changes in the composition of gut microbiome because the 
profile of gut microorganisms in human with type 2 diabetes is different from that 
without type 2 diabetes (a control group) [33]. SCFAs are known to have a signifi-
cant impact on the energy homeostasis, i.e., controlling the energy metabolism; 
therefore, modulation of SCFAs could be a nutritional target to prevent diseases 
associated with metabolism disorders, for example, type 2 diabetes and obesity 
[34]. Gut microbiome is also linked with food allergy in human, and changes in the 
Figure 3. 
Structures of SCFAs including acetate (9), propionate (10), and butyrate (11).
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population and composition of gut microbiota might cause food allergy [35], and 
the use of gut microbiome is a potential innovative strategy to prevent food allergy 
in human [36]. In an animal model, certain gut bacteria, e.g., Clostridia species, 
might be useful for prevention or therapy of food allergy [37]. Recent investigation 
led by Nagler showed that butyrate (11) (Figure 3) produced by the gut bacterium, 
Anaerostipes caccae, could contribute to the prevention of milk allergy in children 
[38]. Germ-free mice colonized with bacteria in feces of healthy infants can protect 
mice against milk allergy, while those colonized with bacteria in feces of milk 
allergic infants could not protect mice from milk allergy; this result indicates that 
gut microbiotas are involved in milk allergy. Detailed analysis revealed that compo-
sitions of gut bacteria in healthy infants were different from milk allergic infants, 
and the gut bacterium, A. caccae, was the key agent to protect against an allergic 
response to food [38]. A. caccae is a saccharolytic intestinal bacterium producing 
butyrate (11) [39]. It is known that butyrate (11) is a key energy source for colonic 
epithelial cells, regulating energy metabolism and autophagy in the mammalian 
colon [40]. Therefore, butyrate (11) is likely to be the key metabolite responsible 
for the protection of milk allergy [38]. An independent study revealed that a dietary 
supplemented with the bacterium Lactobacillus rhamnosus could promote tolerance 
in infants with cow’s milk allergy by enrichment of butyrate-producing bacterial 
strains [41]. The increased levels of butyrate (11) in feces of infants who received 
the supplement with L. rhamnosus were observed in the most tolerant infants 
against milk allergy [41].
Nicotinamide (12) is an amide derivative of vitamin B3 or niacin or nicotinic 
acid (13) (Figure 4) and is a substrate for nicotinamide adenine dinucleotide 
(NAD), a coenzyme in many important enzymatic oxidation–reduction reac-
tions, for example, electron transport chain, citric acid cycle, and glycolysis. 
Nicotinamide (12) is known to have a role in neuronal systems in the central ner-
vous system, thus implicating in neuronal death and neuroprotection [42]. Recent 
study led by Elinav revealed that nicotinamide (12) produced by the gut bacterium, 
Akkermansia muciniphila, significantly protected the progression of the neuro-
degenerative disease, amyotrophic lateral sclerosis (ALS) [43]. The experiment 
demonstrated that removal of gut microorganisms by treating mice with antibiotics 
could promote the ALS symptoms in mice, indicating that gut microbiome modu-
lated the progress of ALS disease [43]. The study showed that the species of gut 
bacteria in healthy human were different from that in ALS patients; A. muciniphila 
was abundant in healthy people, while Ruminococcus torques and Parabacteroides 
distasonis were relatively abundant in ALS patients. Remarkably, transplantation 
of gut bacteria from human gut to germ-free mice revealed that the gut bacterium 
A. muciniphila improved the ALS symptoms, while the gut bacteria R. torques and 
P. distasonis worsened the ALS symptoms [43]. Detailed analysis found that the gut 
bacterium A. muciniphila provided nicotinamide (12) as a bioactive metabolite that 
improves the ALS symptoms. Indeed, a direct injection of nicotinamide (12) into 
mice with ALS could improve a motor-neuron function. The study in 37 patients 
Figure 4. 
Structures of nicotinamide (12) and niacin or nicotinic acid (13).
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with ALS revealed that the levels of nicotinamide (12) in cerebrospinal fluid of 
ALS patients were lower than that in people without ALS. Moreover, analysis of 
microbial genes involved in nicotinamide synthesis in feces of ALS patients revealed 
that people with ALS had less number of the genes for nicotinamide synthesis; these 
genes were mainly from the gut bacterium A. muciniphila. Therefore, it is likely that 
ALS patients might have less abundance of A. muciniphila in their gastrointestinal 
tract [43]. This work suggests that gut microbiome has a significant link with 
human disease pathophysiology and that there is an opportunity to use microbial 
therapeutic targets for certain diseases. Indeed, a clinical trial on human using the 
gut bacterium, A. muciniphila, in overweight and obese insulin-resistant volunteers 
demonstrated that the gut bacterium could reduce insulin resistance indices and 
could lower the levels of circulating insulin and blood cholesterol, thus improving 
the profile of blood lipid and insulin sensitivity [44]. This microbial therapeutic 
approach is safe and may be applied for the treatment of overweight or obese 
insulin-resistant people.
It is known that gut microbiota is significantly associated with autism spectrum 
disorder, a form of mental disorder with difficulties in social communication and 
interaction [45]. Intriguingly, a recent study led by Sharon and Mazmanian revealed 
that gut microbiota could produce neuroactive metabolites which contribute to the 
pathophysiology of autism spectrum disorder, thus regulating behaviors in mice 
[46]. The experiment showed that germ-free mice receiving gut microbiota from 
human donors with autism spectrum disorder could induce autistic behaviors in 
mice. The metabolites produced by gut bacteria, 5-aminovaleric acid (14) and 
taurine (15) (Figure 5), were found to modulate behaviors related to autism spec-
trum disorder. Both 5-aminovaleric acid (14) and taurine (15) are GABAA receptor 
agonists [47, 48]. Levels of 5-aminovaleric acid (14) in mice with autism spectrum 
disorder were significantly lower than that in the control mice, while levels of tau-
rine (15) in mice with autism spectrum disorder were ca. 50% less than the control 
group [46]. Administration of 5-aminovaleric acid (14) and taurine (15) to mice 
with autism spectrum disorder could improve repetitive and social behaviors, i.e., 
modulating neuronal excitability in mice brain and improving behavioral abnor-
malities [46]. This finding suggests that autism spectrum disorder is also related 
to the influence of gut microbiota; therefore microbiome interventions using fecal 
microbiota transplantation, as well as supplementation with metabolites produced 
by gut microorganisms or with probiotics, may improve the quality of life for people 
with autism spectrum disorder.
Gut microbiome substantially contributes to human health and diseases, and 
the metabolites produced by gut microbiome mentioned earlier underscore the 
importance of gut microorganisms in health and certain diseases in human. Health 
and diseases of individuals partly rely on the conditions of gut microbiome whether 
they have healthy gut microbiota or unhealthy ones. Gut microbiota is therefore 
considered as a “hidden” or “forgotten” human organ [12], involving in pathology 
of Alzheimer’s disease [49], endocrine organ involving metabolic diseases [50], and 
Figure 5. 
Structures of 5-aminovaleric acid or 5-aminopentanoic acid (14) and taurine or 2-aminoethanesulfonic  
acid (15).
7Contribution of Gut Microbiome to Human Health and the Metabolism or Toxicity of Drugs…
DOI: http://dx.doi.org/10.5772/intechopen.92840
chronic gastrointestinal disease [51]. Moreover, gut microbiota is also considered as 
an “invisible” organ that controls and manipulates the function of drugs [52]. The 
imbalance of gut microbiota, or known as dysbiosis, leads to unhealthy conditions 
for human or even causes certain diseases. Therefore, the use of gut microbiota as 
a therapeutic target for treatments of human diseases is an emerging approach for 
many diseases, for example, Parkinson’s disease [53], cardiovascular disease [54], 
metabolic disorders [55], hepatocellular carcinoma [56], nonalcoholic fatty liver 
disease [57], food allergy [58], and heart failure [59]. Supplementation with probi-
otics or with health-promoting bacteria is a possible therapeutic method and may 
widely be used in the near future. Fecal microbiota transplantation or supplementa-
tion with metabolites from gut microorganism needs more clinical studies; the two 
approaches will be a challenging research on gut microbiota in the near future.
3. Interactions of gut microbiome and drugs and/or natural products
It is estimated that a total mass of bacteria in the human body is around 0.2 kg 
(for people with a weight of 70 kg) and that the densities of commensal microor-
ganisms in the human gastrointestinal tract ranged from 108 to 1011 bacterial cells/g 
[60]. Oral administration of drugs delivers drugs to the gastrointestinal tract that 
contains high densities of gut microorganisms, which could encode 150-fold more 
genes than those of the human genome [61]; therefore, gut microbes are able to 
encode many enzymes with drug-metabolizing potential [62]. Gut microbiota is 
recognized as an “invisible organ” responsible for controlling drug functions and 
modulation of drug metabolism processes [52]. Normally, antibiotic drugs give 
direct effects toward microorganisms in the human gastrointestinal tract, providing 
either negative or positive (beneficial) effects to the composition of gut microbiota 
[63]. However, intestinal microbiota have many important roles in maintenance 
of human health; therefore, perturbation of gut microbiome by antibiotics could 
give negative impact to human, for example, loss of colonization resistance that 
can prevent invading microorganisms colonizing in the human gastrointestinal 
tract [64]. In addition to antibiotic drugs, a recent study led by Typas demonstrated 
that nonantibiotic drugs also gave extensive impact on human gut bacteria because 
around 24% of 1197 drugs showed antibacterial activity toward at least one strain of 
gut bacteria [65]. This is considered as “antibiotic-like side effects” of nonantibiotic 
drugs, which could potentially promote antibiotic resistance that is one of the major 
public health problems worldwide. This finding provides essential information for 
drug discovery research, i.e., addressing a potential new side effect of drugs and 
repurposing of nonantibiotic drugs as antibacterial agents.
The next sections will highlight the interactions of gut microbiome, especially 
the chemistry of the drug metabolites produced by gut microorganisms, toward 
certain drugs and natural products. The metabolism of drugs or natural products 
by gut microbiome could lead to the production of bioactive metabolites, which 
have either beneficial effects or negative properties (i.e., reducing efficacy of drugs 
or natural products). The study on the interactions of gut microbiota and drugs 
or natural products as part of drug development process is discussed in the next 
sections.
3.1 Interactions of gut microbiome and commonly used drugs
Once drugs enter the human gastrointestinal tract, they encounter trillions 
of microorganisms, which are able to encode 150-fold more genes than human 
genome [61]. A number of enzymes encoded by gut microbial genes catalyze the 
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biotransformation of drugs, producing bioactive metabolites, which have effects on 
human health [60]. Advances in liquid chromatography-mass spectrometry (LC–
MS) technology allow the identification of the metabolites produced by gut micro-
biome, as well as detailed study of pharmacokinetics of drugs and their metabolites, 
while genome sequencing substantially assists the identification of genes encoding 
enzymes in gut microorganisms. Zimmermann and co-workers investigated the 
drug metabolism of an antiviral nucleoside drug, brivudine (16), which is used for 
the treatment of herpes zoster virus; the study was performed using mice inocu-
lated with mutant microbiota [66]. It was found that the bioconversion of brivudine 
(16) to bromovinyluracil (18) (or 5-(E)-(2-bromovinyl)uracil) was achieved by 
enzymes from both mammalian cells and gut microbial communities isolated from 
mice, suggesting that both host and microbiota are capable of such biotransforma-
tion (Figure 6). Previously, intestinal anaerobic bacteria were found to convert 
another antiviral drug, sorivudine (17), to bromovinyluracil (18) (Figure 6) [67].
Gut bacteria, Bacteroides thetaiotaomicron and B. ovatus, were the major species 
having the highest metabolic activity to convert brivudine (16) to bromovinyluracil 
(18) [66]. Comparison of serum kinetics of brivudine (16) and bromovinyluracil 
(18) in conventional (a control with bacteria) and germ-free mice after feeding 
with the drug brivudine (16) suggested that intestinal bacteria contributed to the 
amount of bromovinyluracil (18) in serum because the level of bromovinyluracil 
(18) in conventional mice serum was five times higher than that of germ-free mice 
[66]. The gene, bt4554, encoding the enzyme purine nucleoside phosphorylase 
necessary for the metabolism of brivudine (16) is present in B. ovatus and con-
served in the bacterial phylum Bacteroidetes; the expression of the gene bt4554 is 
a rate-limiting step [66]. The gut bacterium, B. thetaiotaomicron, was found to 
completely metabolize the drug brivudine (16) to bromovinyluracil (18), which is 
absorbed from both the cecum and colon. This study was also able to predict the 
levels in serum and sources of the metabolite bromovinyluracil (18) derived from a 
drug sorivudine (17) (Figure 6) [66].
Zimmermann and co-workers also used clonazepam (19) (Figure 7), an anti-
convulsant and antianxiety drug, as a model [66]; the metabolism of this drug in 
rats gave metabolic products through nitroreduction, oxidation, glucuronidation, 
and enterohepatic cycling [68]. After an oral administration of a drug clonazepam 
(19) to mice, 7-NH2-clonazepam (20) and 7-NH2-3-OH-clonazepam (21) were 
found as major metabolites in serum of the conventional mice (Figure 7). The 
host-microbiome pharmacokinetic model revealed that 7-NH2-clonazepam (20) in 
serum was substantially from a microbial contribution. Experiments also revealed 
that intestinal microbes could convert glucuronyl-3-OH-clonazepam (23) to 
3-OH-clonazepam (22), which in turn transformed to 7-NH2-3-OH-clonazepam 
(21) by microbial reduction (Figure 7) [66]. The study established a pharmacoki-
netic model that can predict microbiome or host (human) contributions to drug 
Figure 6. 
Biotransformation of antiviral drugs brivudine (16) and sorivudine (17) to bromovinyluracil (18) by gut 
bacteria.
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metabolism, e.g., the ability to distinguish drug-metabolizing activity by human or 
gut bacteria [66]. This research model is particularly useful for the study on drug 
metabolism in an animal model.
Gut microbiome has potential ability to metabolite many drugs, thus affecting 
the therapeutic efficacy due to lower concentrations of drugs. The study on the drug 
metabolism of 271 commonly used drugs by gut bacteria revealed that, after incu-
bation of drugs with gut bacteria, the levels of 176 drugs (accounting for two thirds 
of 271 drugs) were significantly reduced, indicating that these drugs were metabo-
lized by gut bacteria [62]. Intriguingly, each bacterial strain (from 76 human gut 
bacterial strains) could metabolize up to 11–95 drugs [62]. This result suggests that, 
when designing the drug molecules, the drug metabolism by gut microbes should 
be seriously considered, particularly the drugs delivered by an oral administration. 
Therefore, the action of gut microbiome toward individual drug candidates should 
also be evaluated during the drug development process. Untargeted metabolomics 
analysis is used to identify products derived from drug metabolism by gut bacteria, 
and it could properly identify the metabolites from microbial metabolism of drugs 
[62]. Some drugs, for example, paliperidone, sulfasalazine, and pantoprazole, were 
previously investigated for their metabolism by gut microbes [69]. Detailed analysis 
by high-resolution mass spectrometry (HRMS) revealed that drugs with an acetyl 
ester or an alkene functional group, such as norethisterone acetate (24), drospire-
none (25), and roxatidine acetate (26), were metabolized through either deacety-
lation (removing C2H2O) or hydrogenation (adding H2) by gut bacteria (Figure 8) 
[62]. Gut bacteria metabolized drugs with aliphatic hydroxyl or amine functional 
group such as dasatinib (27), fluphenazine (28), and primaquine (29) through 
propionylation (adding C3H4O), giving their corresponding O- or N-propionyl 
products 30, 31, and 32, respectively (Figure 8). The HRMS data clearly indicated 
the mass difference of 56.026 unit of a propionyl group between the drug and its 
corresponding derivative [62].
Zimmermann and co-workers investigated the metabolism of drug in mice 
model and in human gut microbial communities using a corticosteroid drug, dexa-
methasone (33), as a model (Figure 9) [62]. It is known that this class of drug is 
metabolized by the bacterium Clostridium scindens through the side-chain cleavage, 
known as the desmolytic activity, to produce the active androgen form of the drug, 
dexamethasone-desmo (34) (Figure 9) [70, 71]. Levels of dexamethasone-desmo 
Figure 7. 
Biotransformation of clonazepam (19) to the metabolites 20–23 by human intestinal microbes.
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(34) were measured after an oral administration of dexamethasone (33) to germ-
free mice and to mice that have only one bacterial species of C. scindens, techni-
cally known as gnotobiotic mice (GNC. scindens). Although dexamethasone (33) was 
found in the cecum of germ-free mice and gnotobiotic mice, the levels of the drug 
were significantly reduced in gnotobiotic mice, suggesting that the bacterium C. 
scindens associated in these mice is involved in the drug metabolism. Accordingly, 
levels of the androgen form of the drug, dexamethasone-desmo (34), which are 
derived from the metabolism of dexamethasone (33), were higher in both serum 
and cecum of gnotobiotic mice than that of germ-free mice [62]. Moreover, similar 
corticosteroid drugs, i.e., prednisone (35), prednisolone (36), cortisone (37), and 
cortisol (38), were also metabolized by the intestinal bacterium C. scindens through 
the desmolytic activity, giving the metabolite products of prednisone-desmo 
(39), prednisolone-desmo (40), cortisone-desmo (41), and cortisol-desmo (42), 
respectively (Figure 9). However, when incubating the drug dexamethasone (33) 
with gut bacterial community isolated from 28 healthy human participants under 
anaerobic condition, the drug-metabolizing activity had considerable interpersonal 
variation as suggested by level variations of the drug metabolite, dexamethasone-
desmo (34) [62]. This result implies that dexamethasone (33) is also metabolized 
by other gut bacterial species, not only C. scindens.
Figure 8. 
Structures of the drugs, norethisterone acetate (24), drospirenone (25), and roxatidine acetate (26) and 
biotransformation of dasatinib (27), fluphenazine (28), and primaquine (29) to their corresponding products 
30, 31, and 32, respectively, by gut bacteria.
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Systematic identification of drug-metabolizing genes encoded by gut bacteria 
provides the mechanistic insights into drug metabolism in human [62]. Genes 
of the gut bacterium Bacteroides thetaiotaomicron were cloned into Escherichia 
coli, leading to the identification of new 16 gene products, which were able to 
metabolite 18 drugs to 41 different metabolites [62]. Certain gene products have 
specificity and cross-activity, and gene deletion and complementation techniques 
revealed the mechanisms of individual gene products. For instance, the bt2068 
gene encodes the enzyme that could reduce (adding H2) norethisterone acetate 
(24) (Figure 8), as well as other similar steroid drugs such as levonorgestrel 
and progesterone, while the bt2367 gene encodes acyltransferase that converts 
Figure 9. 
Gut bacterial metabolism of corticosteroid drugs, dexamethasone (33), prednisone (35), prednisolone (36), 
cortisone (37), and cortisol (38), to their respective products 34, 39, 40, 41, and 42 via the desmolytic activity.
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the drug pericyazine (43) to both acetyl- and propionyl-pericyazine products, 
e.g., acetyl-O-pericyazine (44) and propionyl-O-pericyazine (45), respectively 
(Figure 10) [62]. It is known that the metabolism products of a drug diltia-
zem (46) are N-desmethyldiltiazem (47), N,N-didesmethyldiltiazem (48), 
O-desmethyldiltiazem (49), N,O-didesmethyldiltiazem (50), desacetyldiltiazem 
(51), desacetyl-N-desmethyldiltiazem (52), desacetyl-N,N-didesmethyldiltiazem 
(53), desacetyl-O-desmethyldiltiazem (54), and desacetyl-N,O-didesmethyldilti-
azem (55) (Figure 10) [72]. The gene bt4096 in gut bacteria is responsible for the 
deacetylation of diltiazem (46) and its metabolites 47–50 to give their correspond-
ing deacetylated products 51–55, respectively (Figure 10) [62]. This study suggests 
that gut bacteria substantially contribute to drug metabolism in the human gastro-
intestinal tract, and the metabolism of drug candidates by gut microbiome should 
be studied as a part of the drug development processes.
The drug metabolism by gut microbiome can give negative effects to drug effi-
cacy, thus leading to the decrease in efficiency and potency of certain drugs. L-dopa 
or levodopa (56) (Figure 11) is the first-line drug for the treatment of Parkinson’s 
disease; the metabolism of this drug by gut microbiome provides negative effects 
for Parkinson’s patients. The drug L-dopa (56) can cross the blood–brain barrier, 
entering the central nervous system and then transforming to a neurotransmitter, 
Figure 10. 
Metabolism of pericyazine (43) to acetyl-O-pericyazine (44) and propionyl-O-pericyazine (45) and 
metabolism of diltiazem (46) to the metabolite products 47–55 by gut bacteria.
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dopamine (57), by the enzyme pyridoxal phosphate l-amino acid decarboxylase 
(Figure 11). It is known that intestinal microflora (gut microbiome) can metabolite 
L-dopa (56) [73] and that the formation of m-tyramine (58) from L-dopa (56) is 
a side effect of this drug for parkinsonism (Figure 11) [74]. A neurotransmitter, 
dopamine (57), is the only active agent needed for the treatment of parkinson-
ism, and it should be formed from L-dopa (56) at the central nervous system 
after L-dopa (56) crossing the blood–brain barrier. However, the generation of 
dopamine (57) from the drug L-dopa (56) can occur at the human gastrointestinal 
tract (known as peripheral metabolism), not at the central nervous system, thus 
giving undesirable side effects. To prevent this peripheral metabolism, an inhibitor 
of pyridoxal phosphate l-amino acid decarboxylase, carbidopa (59) (Figure 11), is 
coadministered with the drug L-dopa (56). It is known for many years that micro-
organisms can decarboxylate L-dopa (56) to dopamine (57), which in turn under-
goes the dehydroxylation reaction to give m-tyramine (58) [75]. The treatment of 
L-dopa (56) is improved when patients receive broad-spectrum antibiotics, which 
suppress the growth of gut bacteria, indicating that gut bacteria are involved in the 
decrease of therapeutic efficiency of L-dopa (56) [76]. Therefore, gut microbiome 
can potentially reduce the drug efficacy of L-dopa (56) through their metabolic 
activities toward the drug.
Recent study led by Prof. Balskus revealed that the gut bacterium Enterococcus 
faecalis has the tyrDC gene encoding the enzyme tyrosine decarboxylase that is able 
to decarboxylate both L-dopa (56) and an amino acid, tyrosine [77]. Moreover, the 
gut bacterium Eggerthella lenta has the dadh gene encoding a molybdenum cofactor-
dependent dopamine dehydroxylase, which is the enzyme responsible for the 
dehydroxylation of dopamine (57) to m-tyramine (58) (Figure 11). The metabolism 
of L-dopa (56) and dopamine (57) in complex gut microbiotas of Parkinson’s 
patients is dependent on the tyrDC and dadh genes [77]. The study demonstrated 
that carbidopa (59), an inhibitor of pyridoxal phosphate l-amino acid decarbox-
ylase, failed to prevent L-dopa (56) metabolism in complex gut microbiotas of 
Parkinson’s patients [77]. However, another inhibitor, (S)-α-fluoromethyltyrosine 
Figure 11. 
Bioconversion of L-dopa (56) to dopamine (57) and m-tyramine (58) by gut bacteria and structures of 
inhibitors of amino acid decarboxylases, carbidopa (59), (S)-α-fluoromethyltyrosine (60), benserazide (61), 
and methyldopa (62).
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(60) (Figure 11), could prevent the decarboxylation of L-dopa (56) that is from 
the metabolic activities of both the bacterium E. faecalis and complex gut micro-
biotas of Parkinson’s patients [77]. In a mouse model, levels of the drug L-dopa 
(56) increased in serum when coadministered (S)-α-fluoromethyltyrosine (60) 
with L-dopa (56) to mice colonized with the gut bacterium E. faecalis [77]. An 
independent study led by Prof. Aidy also identified the tdc gene responsible for 
tyrosine decarboxylases in the gut bacterium E. faecium; bacterial tyrosine decar-
boxylases efficiently convert the drug L-dopa (56) to dopamine (57) [78]. Aidy and 
co-workers also found that carbidopa (59) in L-dopa (56) combination therapy did 
not inhibit the activities of decarboxylase enzymes in gut bacteria, E. faecalis and 
E. faecium [78]. Moreover, other decarboxylase inhibitors, benserazide (61) and 
methyldopa (62) (Figure 11), also failed to inhibit the decarboxylase activity of gut 
bacteria toward the drug L-dopa (56). These studies demonstrated gut microbiota 
significantly reduced the levels of the drug L-dopa (56) in a body, thus contributing 
to the higher dosages required for the Parkinson’s patients that have gut microbiome 
with high metabolism toward the drug L-dopa (56). Variations in gut microbiota 
among Parkinson’s patients might contribute to the different responses, i.e., harm-
ful side effects and decreased efficacy, to the drug L-dopa (56). Therefore, gut 
microbiota plays a critical role in the drug metabolism and considerably contributes 
to treatment outcomes of this drug.
Gut microbiota can improve therapeutic efficiency of certain drugs for par-
ticular treatments. Cancer immunotherapy is relatively new for cancer treatment 
using human immune system to control and eradicate cancer cells, and it is more 
precise and personalized, thus providing more effectiveness with fewer side effects 
than other cancer treatments. Gut microbiota was found to play a role in cancer 
immunotherapy targeting CTLA-4, a protein receptor downregulating the immune 
system, because anticancer effects of CTLA-4 blockade were found to depend on 
gut bacteria of Bacteroides species, e.g., Bacteroides thetaiotaomicron or B. fragilis 
[79]. The study demonstrated that germ-free mice did not show the response to 
CTLA blockade, thus defecting an anticancer property of the drug. Indeed, this 
drug deficiency could be improved by gavage with the gut bacterium B. fragilis 
through immunization with the bacterium polysaccharides or by adoptive transfer 
of B. fragilis-specific T cells. Therefore, this research study demonstrates that the 
gut bacterium could help patients treated with a monoclonal antibody drug for the 
treatment of cancer targeting CTLA-4 [79].
Gut microbiome also improves therapeutic effect of a cancer immunotherapy 
targeting immune checkpoint inhibitor via the PD-1/PD-L1 pathway [59]. 
Antibiotics are found to give negative effects for patients treated with cancer 
immunotherapies as they inhibit the efficacy of immune checkpoint inhibitor drug 
that targets the programmed cell death receptor of the PD-1/PD-L1 pathway [59]. 
Moreover, suppression of growth of gut bacteria by antibiotic drugs leads to the 
decrease of drug efficacy, suggesting that gut microorganisms are important for this 
cancer therapy. The study demonstrated that gut microbiota provided significant 
effects on cancer immunotherapies targeting the PD-1/PD-L1 interaction because 
there was substantial association between commensal microorganisms and thera-
peutic response of anticancer drug that inhibits the activity of PD-1 and PD-L1 
immune checkpoint proteins [80]. Gut bacteria including Collinsella aerofaciens, 
Enterococcus faecium, and Bifidobacterium longum were found to be associated with 
the improvement of this cancer immunotherapy. Intriguingly, reconstitution of 
germ-free mice with fecal samples from patients with good drug response could 
help to control tumor, leading to better efficacy of anti-PD-L1 cancer therapy [80]. 
An independent study revealed that the gut bacterium Akkermansia muciniphila 
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assists cancer immunotherapy targeting the PD-1/PD-L1 interaction toward 
epithelial tumors [81]. The study on fecal microbiota transplantation demonstrated 
that germ-free or antibiotic-treated mice receiving gut bacteria from patients with 
good response to cancer immunotherapy have significant therapeutic improvement, 
while those receiving the samples from nonresponding patients do not have such 
improvement for cancer immunotherapy [81]. Restoration of the drug efficacy in 
germ-free mice receiving the samples from nonresponding patients was simply 
achieved by oral supplementation with the gut bacterium A. muciniphila, indicating 
the benefit of gut microbiota for this cancer immunotherapy. Another independent 
research also found similar benefits of gut microbiota on anti-PD-1 immunotherapy 
in melanoma patients; this study investigated microbiome samples from 112 
patients with metastatic melanoma and found that there were substantial differ-
ences in the composition and diversity of gut microbiome obtained from patients 
with good drug response and from nonresponding patients [82]. Patients with good 
response to immunotherapeutic PD-1 blockade have abundance of gut bacteria 
of the family Ruminococcaceae and Faecalibacterium, while patients with poor 
response to immunotherapeutic PD-1 blockade tend to have relative abundance 
of Bacteroidales. It is possible that patients with a favorable gut microbiome, e.g., 
Ruminococcaceae and Faecalibacterium, toward the immunotherapeutic PD-1 block-
ade therapy have improved systemic and immune responses mediated by certain 
factors such as improvement of effector T cell function in the periphery, increase of 
antigen production, and improvement of the tumor microenvironment [82].
Gut microbiota also has an important role in chemotherapy for cancer treat-
ment because they can modulate drug efficacy, for example, eliminating the 
anticancer properties of the drug or mediating toxicity [83]. Cyclophosphamide 
(63) (Figure 12) is a drug used in cancer chemotherapy for many types of cancers, 
as well as for autoimmune diseases, and its mechanism is through the stimula-
tion of anticancer immune responses. In a mouse model, the composition of gut 
microbiota is changed after administration of cyclophosphamide (63), and this 
drug induces the translocation of certain Gram-positive bacteria into secondary 
lymphoid organs. Gut bacteria could stimulate certain immune responses beneficial 
to cancer therapy. Germ-free mice carrying tumor treated with antibiotics to kill 
Gram-positive bacteria had less therapeutic response, and their tumors exhibited 
resistance to the drug cyclophosphamide (63), suggesting that gut microbiota 
improves anticancer immune response [84]. Gut bacteria, Enterococcus hirae and 
Barnesiella intestinihominis, were found to help cyclophosphamide-induced thera-
peutic immunomodulatory response, thus improving the efficacy of this alkylating 
immunomodulatory drug [85].
Figure 12. 
Structure of an anticancer drug, cyclophosphamide (63).
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The research studies mentioned earlier demonstrate the interactions of drugs 
and gut microbiome that provide beneficial effects on cancer therapy. However, 
interactions of gut microbiome and drugs can also give negative influence in cancer 
treatment, for example, the treatment of an anticancer drug, gemcitabine (64) or 
2′,2′-difluorodeoxycytidine (Figure 13), which is a derivative of cytidine nucleoside 
base. A research led by Straussman showed that the bacterium Mycoplasma hyorhinis 
was found to be the cause of gemcitabine (64) resistance in colon carcinoma models 
[86]. In a colon cancer mouse model, M. hyorhinis could metabolize gemcitabine 
(64) to the corresponding deaminated derivative, 2′,2′-difluorodeoxyuridine (65), 
that does not have anticancer activity (Figure 13). The conversion of gemcitabine 
(64) to 2′,2′-difluorodeoxyuridine (65) was previously reported [87], and the 
nucleoside-catabolizing enzymes, i.e., cytidine deaminase, in the bacterium, M. 
hyorhinis, were also identified [88]. Straussman and co-workers analyzed genes and 
genomes of 2674 bacterial species and found that most of the Gammaproteobacteria 
class had the gene coding for the enzyme cytidine deaminase, thus potentially 
mediating gemcitabine resistance [86]. In a mouse model of colon carcinoma, mice 
receiving an antibiotic, ciprofloxacin, showed a good response to the anticancer 
drug gemcitabine (64), indicating that suppression of the growth of certain bacte-
ria led to the improvement of the drug efficacy. Investigation of human pancreatic 
ductal adenocarcinoma collected from pancreatic cancer surgery revealed that there 
were intratumor bacteria, mainly belonging to the class Gammaproteobacteria such 
as Enterobacteriaceae and Pseudomonadaceae families in these samples; the intratu-
mor bacteria can mediate resistance to chemotherapy of the drug gemcitabine (64) 
[86]. Therefore, the metabolism of the drug gemcitabine (64) to 2′,2′-difluorode-
oxyuridine (65) by gut microbiota provides the negative effects for cancer treat-
ment. This study underscores the importance of the research on drug metabolism 
by gut microbiome, which should be investigated for the new drug candidates 
during the drug development processes.
Additional example for the negative effects of gut microbiota for cancer 
chemotherapy is the treatment of colorectal cancer with the drugs, oxaliplatin 
(66) and fluorouracil or 5-FU (67) (Figure 13); the gut bacterium Fusobacterium 
Figure 13. 
Biotransformation of gemcitabine (64) to its metabolite 2′,2′-difluorodeoxyuridine (65); structures of 
anticancer drugs, oxaliplatin (66) and fluorouracil or 5-FU (67), and autophagy lysosomal inhibitor, 
chloroquine (68).
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nucleatum was found to promote resistance to chemotherapy for colorectal cancer 
[89]. Analysis of colorectal cancer tissues collected from patients with recurrence or 
without recurrence of cancer revealed that the bacterium F. nucleatum is associated 
with the recurrence of colorectal cancer, which is derived from chemoresistance 
toward the drugs [89]. Cultivation of colorectal cancer cells co-cultured with F. 
nucleatum revealed that the bacterium potentially activated an autophagy pathway 
in colorectal cancer cells. An addition of a known autophagy lysosomal inhibitor, 
chloroquine (68) (Figure 13), could inhibit autophagic flux in the F. nucleatum-
cultured cells, confirming the autophagy activation induced by the gut bacterium F. 
nucleatum [89]. Moreover, this bacterium reduced cell apoptosis of colorectal cancer 
cells, indicating that it specifically induced resistance toward the drugs oxaliplatin 
(66) and fluorouracil (67). Co-cultured cancer cells with the bacterium F. nuclea-
tum and treated cancer cells with the drugs oxaliplatin (66) and fluorouracil (67) 
in the presence of autophagy lysosomal inhibitor, chloroquine (68), could eradicate 
chemoresistant effect, strongly confirming that the bacterium F. nucleatum induced 
chemoresistance through the autophagy pathway [89]. Detailed mechanistic study 
revealed that the bacterium F. nucleatum mediated chemoresistance through the 
TLR4 and MYD88 signaling pathway [89]. An independent study showed that 
the gut bacterium F. nucleatum is a diagnostic marker of colorectal cancer because 
patients with this cancer generally have high density of this bacterium in tumor cells 
[90]. Several studies have shown the prevalence of the bacterium F. nucleatum in 
colorectal tissues and fecal samples of patients, and those with high density of this 
bacterium tend to have lower rate of survival [91]. Therefore, manipulation of the 
bacterial population of F. nucleatum might be useful for the treatment of colorectal 
cancer, and this bacterium is potentially a diagnostic and/or prognostic marker for 
colorectal cancer.
In addition to drug metabolism, gut microbiota is also involved in drug–drug 
interactions when patients take two drugs at the same time, particularly when 
using antibiotics together with other drugs. Several studies have demonstrated 
the effects of antibiotic drugs on the metabolic activities of gut microbiota toward 
drugs and phytochemicals [92]. An example of a drug–drug interaction is the 
contribution of an antibiotic drug, amoxicillin (69), to a nonsteroidal anti-inflam-
matory drug aspirin (70) (Figure 14) [93]. It is worth mentioning that aspirin (70) 
is used not only for a pain reliever but also for primary prevention of cardiovascular 
disease [94] and cancer chemoprevention [95]. Recent study showed that amoxi-
cillin (69) potentially affected the composition of gut microbiota by reducing 
number and species of intestinal bacteria in rats; the abundance of the gut bacteria, 
Prevotella copri and Helicobacter pylori, was reduced significantly after rats receiv-
ing amoxicillin (69) [93]. Gut microorganisms in rats could metabolite aspirin 
(70) to salicylate or salicylic acid (71) (Figure 14). Salicylate is a conjugate base 
of salicylic acid (71). It is known that the drug aspirin (70) is not responsible for a 
pain relief, but its metabolite, salicylic acid (71), is the active metabolite respon-
sible for a pain relief with anti-inflammatory effect [96]. Therefore, gut microbiota 
plays an important role in the biotransformation of the drug aspirin (70) into the 
active metabolite, salicylic acid (71). After an oral administration of an antibiotic 
drug amoxicillin (69) to rats, the reduction of the metabolism of aspirin (70) into 
salicylic acid (71) was observed, suggesting the decrease of gut microbiota by 
amoxicillin (69) led to the reduction of the biotransformation of aspirin (70) into 
salicylic acid (71). Further study on the pharmacokinetics of aspirin (70) in rats 
revealed that amoxicillin (69) significantly affected the pharmacokinetic proper-
ties of aspirin (70) [93]. This study indicates that changes of the composition of gut 
microbiome by antibiotic drugs could substantially disturb the therapeutic effect 
of other drugs.
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Previous study also showed that antibiotics substantially reduced the metabolic 
activity of gut microbiota toward aspirin (70), leading to the reduction of an 
antithrombotic effect of aspirin (70) [97]. Moreover, environmental changes, e.g., 
high-altitude hypoxia, also give effects on the pharmacokinetics and pharmacody-
namics of aspirin (70) because of the changes in gut microbiota [98]. In an animal 
model, the plateau hypoxic environment affected the composition of gut microbi-
ome because it increased the bacterial species of Bacteroides in rat feces but reduced 
numbers of the bacteria of the genus Prevotella, Coprococcus, and Corynebacterium. 
Changes in gut microbiome affected the metabolism of aspirin (70), thus altering 
the bioavailability of aspirin (70) in patients [98]. Plateau hypoxic environment 
also has the effects on the drug nifedipine (72), which could be metabolized by 
gut microorganisms (Figure 14) [99]. Nifedipine (72) is a drug for the treatment 
of hypertension, precordial angina, and certain vascular diseases. Plateau hypoxic 
environment was found to alter the composition of gut microbiota in an animal 
model, thus affecting the bioavailability of nifedipine (72) [99].
Recent study led by Kittakoop revealed that valproic acid or valproate (73) 
(Figure 15), an anticonvulsive drug used for treatments of epilepsy and bipolar 
disorder, had effects on the biosynthesis of fatty acids in microorganisms includ-
ing representative gut microbiome [100]. Valproic acid (73) is also an epigenetic 
modulator, acting as an inhibitor of histone deacetylase [101]. Initially, Kittakoop 
and co-workers employed “One strain many compound” (OSMAC) approach using 
the marine fungus Trichoderma reesei treated with an epigenetic modulator, valproic 
acid (73), aiming to modulate the fungus T. reesei to produce new natural products, 
which are secondary metabolites. However, valproic acid (73) was found to have the 
effects on the biosynthesis of fatty acids, which are primary metabolites, instead 
of natural products that are secondary metabolites [100]. The study revealed that 
valproic acid (73) at a concentration of 100 μM could either inhibit or induce the 
biosynthesis of certain fatty acids in fungi, yeast, and bacteria. Valproic acid (73) 
inhibited the biosynthesis of palmitoleic acid (C16:1), α-linolenic acid (C18:3), ara-
chidic acid (C20:0), and lignoceric acid (C24:0) in the fungus Fusarium oxysporum, 
while it induced the production of α-linolenic acid (C18:3) in the fungus Aspergillus 
Figure 14. 
Structures of amoxicillin (69), aspirin (70) and its metabolite, salicylate or salicylic acid (71), and  
nifedipine (72).
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aculeatus [100]. The bacterium of the genus Pediococcus is commonly found as gut 
microbiome in humans and animals [102]; valproic acid (73) was found to inhibit 
the production of lignoceric acid (C24:0) in the bacterium, Pediococcus acidilactici 
[100]. The yeast Candida utilis was found as gut microbiome in pediatric patients 
with inflammatory bowel disease [103]; valproic acid (73) inhibited the biosynthe-
sis of palmitoleic acid (C16:1) and α-linolenic acid (C18:3) in C. utilis [100]. The 
yeast Saccharomyces cerevisiae was previously found as a prevalent gut microbiome 
in human [104], and the drug valproic acid (73) was found to inhibit the production 
of α-linolenic acid (C18:3) in the yeast S. cerevisiae [100]. Interestingly, valproic 
acid (73) could induce the biosynthesis of trans-9-elaidic acid (74) (Figure 15) in 
the yeast Saccharomyces ludwigii [100]. In human, trans-9-elaidic acid (74) could 
increase intracellular Zn2+ in macrophages and inhibit β-oxidation in peripheral 
blood macrophages [105, 106]; this suggests that the production of trans-9-elaidic 
acid (74) in gut microorganisms induced by the drug valproic acid (73) may 
indirectly give the effects to human. Valproic acid (73) also had effects on the bio-
synthesis of polyketides because it substantially reduced the production of austdiol 
(75) (90% reduction) and quadricinctone A (76) (50% reduction) (Figure 15), 
which are the polyketides of the fungus Dothideomycetes sp. [100]. The biosynthesis 
of fatty acids is considerably similar to that of polyketides, i.e., sharing the same 
catalytic roles and biosynthetic precursors [107]. Therefore, the drug valproic acid 
(73) possibly gives effects on the biosynthetic pathways of both fatty acids and 
polyketides because of their biosynthetic similarities. Gut microbes have biosyn-
thetic gene clusters involving in the biosynthesis of many bioactive natural products 
including polyketides [108]; some natural products produced by gut microbiome 
have biological activities. This study suggests that commonly used drugs could 
potentially give the effects on the biosynthesis of secondary metabolites (natural 
products) of gut microbiome.
3.2 Interactions of gut microbiome and natural products
Traditional medicine and natural products have significant interactions with 
gut microbiome. Many studies revealed that dietary natural products modulating 
gut microbiota are useful for prevention and management of diabetes mellitus 
[109]. Recent study revealed that a traditional Chinese herbal formula and an 
antidiabetic drug, metformin (77) (Figure 16), could improve the treatment of 
Figure 15. 
Structures of valproic acid or valproate (73), trans-9-elaidic acid (74), austdiol (75), and quadricinctone  
A (76).
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type 2 diabetes with hyperlipidemia by enriching certain beneficial species of gut 
bacteria, for example, Faecalibacterium sp. and Blautia [110]. The study was carried 
out in 450 patients with type 2 diabetes and hyperlipidemia, and the profiles of gut 
microbiota were analyzed using fecal samples in patients treated with metformin 
and a traditional Chinese herbal formula. An antidiabetic drug metformin (77) 
and herbal medicine significantly changed the gut microbiota profile that led to 
the enhancement of therapeutic effects of the drugs [110]. The traditional Chinese 
herbal formula used in the study contains the plants including Coptis chinensis, 
Momordica charantia, Rhizoma anemarrhenae, and Aloe vera, as well as red yeast rice 
from the fermentation; this herbal recipe is practically used in clinical application 
[110]. Among the plants used in this formula, Coptis chinensis contains an alkaloid 
berberine (78) (Figure 16). An independent study revealed that berberine (78) 
could significantly change the composition of gut microbiota in high-fat diet-fed 
rats [111]. An alkaloid berberine (78) was able to enrich selectively short-chain 
fatty acid-producing bacteria such as the genus Blautia and Allobaculum [111]. 
Another independent study also revealed that both metformin (77) and berberine 
(78) could change profiles of gut microbiota in high-fat diet-induced obesity in rats 
[112]. Substantial reduction of the diversity of gut microbiota was observed by both 
metformin (77) and berberine (78) because 60 out of the 134 operational taxo-
nomic units were decreased after treatment with both drugs. However, there were 
considerable increases in short-chain fatty acid-producing bacteria, e.g., the genus 
Butyricicoccus, Blautia, Allobaculum, Phascolarctobacterium, and Bacteroides, after 
treatment with both metformin (77) and berberine (78) [112]. Therefore, in addi-
tion to the direct benefit toward the treatment of diabetes and obesity, the drugs, 
metformin (77) and berberine (78), could also improve gut microbiota profile 
by increasing short-chain fatty acid-producing bacteria and thus mediating their 
useful effects on the host [112]. As mentioned earlier in Section 2, gut microbiomes 
that produce short-chain fatty acids provide many beneficial effects on human 
health [24, 25].
Recent study revealed that berberine (78) could prevent ulcerative colitis by 
modifying gut microbiota and regulating T regulatory cell and T helper 17 cell in 
a dextran sulfate sodium-induced ulcerative colitis mouse model [113]. The diver-
sity of gut microbiota was reduced by berberine (78), which markedly interfered 
the abundance of certain bacterial genus such as Bacteroides, Desulfovibrio, and 
Eubacterium. Therefore, the mechanisms of berberine (78) for the prevention of 
ulcerative colitis are by regulating the balance of T regulatory cell and T helper 17 
cell, as well as by modifying gut microbiota [113]. Theobromine (79) (Figure 16) 
is a xanthine alkaloid of cocoa beans and found in chocolate, and its structure is 
closely related to caffeine. A cocoa-enriched diet containing theobromine (79) 
could decrease the intestinal immunoglobulin A secretion and immunoglobulin 
Figure 16. 
Structures of metformin (77), berberine (78), and theobromine (79).
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A-coating bacteria, i.e., the genus of Bacteroides, Staphylococcus, and Clostridium 
[114]. A cocoa-enriched diet had effects on a differential toll-like receptor pattern, 
which led to changes in the intestinal immune system [114]. Moreover, further 
experiments in rats revealed that a diet containing 10% cocoa and a diet supple-
mented with 0.25% theobromine (79) could reduce the gut bacterium Escherichia 
coli, while a diet with 0.25% theobromine (79) reduced the gut bacterial commu-
nity of Clostridium histolyticum, C. perfringens, Streptococcus sp., and Bifidobacterium 
sp. [115]. The amounts of short-chain fatty acids increased after feeding rats with a 
diet containing 10% cocoa and that supplemented with 0.25% theobromine (79), 
while both diets decreased the abundance of immunoglobulin A (IgA)-coated 
bacteria. It is worth mentioning that gut IgA-coated bacteria could potentially cause 
intestinal disease such as inflammatory bowel disease, and eradication of these 
bacteria may prevent or reduce intestinal disease development [116]. Therefore, 
the active natural product theobromine (79) in cocoa able to reduce the amounts 
of immunoglobulin A-coated bacteria, and to modify the profile of gut microbiota, 
provides beneficial effects on human health [115].
It is known that berberine (78) has poor solubility; however, it can show effec-
tiveness for the treatment of certain diseases; therefore, there might be a specific 
mechanism to deliver berberine (78) to an organ system. In an animal model, 
berberine (78) was found to convert to dihydroberberine (80) in an intestinal eco-
system of rats (Figure 17); the metabolite dihydroberberine (80) exhibited much 
better absorption rate than its parent drug, berberine (78) [117]. Incubation of 
berberine (78) with human gut bacteria isolated from gastrointestinal human speci-
mens also produced dihydroberberine (80), and the amounts of dihydroberberine 
(80) obtained from the biotransformation of gut bacteria were higher than that 
obtained from other bacteria, which were not gut bacteria and used as the control. 
This experiment confirmed that gut microbiota could convert berberine (78) into 
its absorbable form, dihydroberberine (80); therefore intestinal microbiota is 
considered to be a “tissue” or an “organ” that is able to transform berberine (78) 
Figure 17. 
Bioconversion of berberine (78) into an absorbable form, dihydroberberine (80), by gut bacteria; absorption 
of dihydroberberine (80) into the intestine wall and nonenzymatic conversion of dihydroberberine (80) to the 
active form berberine (78).
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into an absorbable form, dihydroberberine (80) [117]. Mechanistic study revealed 
that gut microbiome uses the enzyme nitroreductases to catalyze the conversion of 
berberine (78) to dihydroberberine (80) (Figure 17). Dihydroberberine (80) was 
found to be absorbed in intestinal epithelia, but it was reverted to the active form 
berberine (78) soon after entering tissues of the intestinal wall. Detailed analysis 
showed that the conversion of dihydroberberine (80) back to berberine (78) was by 
a nonenzymatic oxidation through multi-faceted factors, for example, superoxide 
anion and metal ions, which occurred in intestinal epithelial tissues (Figure 17) 
[117]. Previous report demonstrated that dihydroberberine (80) in its sulfate form, 
e.g., dihydroberberine sulfate, also showed better absorption in the intestine than 
its parent drug, berberine (78) [118]. Recent independent studies revealed that 
dihydroberberine (80) has interesting biological activities, for example, anti-
inflammatory activity through dual modulation of NF-κB and MAPK signaling 
pathways [119], synergistic effects with an anticancer drug sunitinib on human 
non-small cell lung cancer cell lines by inflammatory mediators and repressing 
MAP kinase pathways [120], and inhibition of ether-a-go-go-related gene (hERG) 
channels expressed in human embryonic kidney 293 (HEK293) cells [121]. It is 
worth mentioning that the metabolite products from gut biomicrobiota, i.e., dihy-
droberberine (80), have different biological activity from its parent drug, berberine 
(78). Therefore, the drug development process should include a research study on 
the metabolism of natural products (as drug candidates) by gut microbiota.
Demethyleneberberine (81), berberrubine (82), jatrorrhizine (83), and thali-
fendine (84) were found as major metabolites in rats after an oral administration 
of berberine (78) (Figure 18) [122]. Comparison of the levels of these metabolites 
in conventional rats (a control group) and pseudo germ-free rats revealed that liver 
and intestinal bacteria were involved in the metabolism and disposition of berber-
ine (78) in vivo. It is worth mentioning that some metabolites from this biotrans-
formation exert important biological activities. For example, demethyleneberberine 
(81) inhibits oxidative stress, steatosis, and mitochondrial dysfunction in a mouse 
Figure 18. 
Biotransformation of berberine (78) to demethyleneberberine (81), berberrubine (82), jatrorrhizine (83), and 
thalifendine (84) by gut bacteria.
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model, which is a potential therapy for alcoholic liver disease [123]. Berberrubine 
(82) was found to reduce inflammation and mucosal lesions in dextran sodium 
sulfate-induced colitis in mice, which might be useful for the treatment of 
ulcerative colitis [124]. Jatrorrhizine (83) could reduce the uptake of 5-hydroxy-
tryptamine and norepinephrine by the inhibition of uptake-2 transporters, thus 
exerting antidepressant-like action in mice [125]. Therefore, the biotransformation 
of berberine (78) by gut bacteria leads to the production of bioactive metabolites, 
which have interesting pharmacological properties; this underscores the impact of 
gut microbiota in the drug development process for natural products.
Since there are interactions between gut microbiota and natural products, 
efforts have been made to use natural compounds for the treatment of gut micro-
biota dysbiosis, which is the imbalance of microorganisms in the human gastroin-
testinal tract. Dysbiosis of gut microbiota is strongly associated with some diseases 
such as type 2 diabetes, inflammatory bowel disease, obesity, and nonalcoholic 
fatty liver disease [16, 126]. Alkaloids of a medicinal plant, Corydalis saxicola, were 
used to prevent gut microbiota dysbiosis in an animal model [127]. Major alkaloids 
in Corydalis saxicola are berberine (78), jatrorrhizine (83), dehydrocavidine (85), 
palmatine (86), and chelerythrine (87) (Figures 18 and 19). Among these alka-
loids, berberine (78), palmatine (86), and chelerythrine (87) are the main active 
principles for the treatment of antibiotic-induced gut microbiota dysbiosis through 
the key enzyme, CYP27A1, which is involved in the biosynthesis of bile acid [127]. 
This study provides insights for the discovery of natural products for the treatment 
of gut microbiota dysbiosis.
Xanthohumol (88) is a prenylflavonoid in hops (Humulus lupulus), which is 
responsible bitter flavor in beer (Figure 20). Xanthohumol (88) has interesting 
pharmacological properties, for example, improving cognitive flexibility in young 
mice [128] and having beneficial effects toward metabolic syndrome-related dis-
eases such as type 2 diabetes and obesity [129]. The comparative study on germ-free 
and human microbiota-associated rats toward the metabolism of xanthohumol (88) 
revealed that gut bacteria could transform xanthohumol (88) to isoxanthohumol 
(89) and 8-prenylnaringenin (90), respectively (Figure 20) [130]. The metabo-
lism of xanthohumol (88) was further studied using human intestinal bacteria, 
Eubacterium ramulus and E. limosum. It is worth mentioning that an independent 
study revealed that the bacteria of the genus Eubacterium are normally abundant in 
the human gastrointestinal tract; their densities in human gut are up to 1010 colony-
forming units/g of intestinal content [131]. Xanthohumol (88) is spontaneously 
converted to isoxanthohumol (89), which is in turn bioconverted to 8-prenylnarin-
genin (90) by the gut bacterium, E. limosum (Figure 20) [132]. 8-Prenylnaringenin 
(90) is biotransformed to O-desmethylxanthohumol (91) by the bacterium E. 
ramulus; this bacterium could also convert O-desmethylxanthohumol (91) to 
desmethyl-α,β-dihydroxanthohumol (92). Moreover, the bacterium E. ramulus was 
Figure 19. 
Structures of dehydrocavidine (85), palmatine (86), and chelerythrine (87).
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able to transform xanthohumol (88) to α,β-dihydroxanthohumol (93) (Figure 20) 
[132]. An independent study in healthy women volunteers revealed that isoxantho-
humol (89) could be bioconverted to 8-prenylnaringenin (90) in human intestine 
and that the bacterial microbiota isolated from fecal samples of female volunteers 
could also biotransform isoxanthohumol (89) to 8-prenylnaringenin (90) [133]. 
Another study demonstrated that 8-prenylnaringenin (90) has potent estrogenic 
property, and it could relieve climacteric symptoms, i.e., vasomotoric complaints 
and osteoporosis, and may be useful for the treatment of menopausal complaints 
[134]. These studies conclusively show that the metabolites produced by gut micro-
biome, i.e., 8-prenylnaringenin (90), are actually bioactive compounds, not the 
parent natural products, and they have different pharmacological activities from 
their parent natural products. Gut microbiome is therefore important for in vivo 
biotransformation of natural products, providing bioactive metabolites responsible 
for therapeutic effects.
Gut microbiome can biotransform natural products to bioactive metabolite 
essentially for therapeutic effects, for example, the biotransformation of isoxantho-
humol (89) to bioactive 8-prenylnaringenin (90) [133]. However, gut microbiome 
can also produce toxic metabolites from the biotransformation of natural products, 
thus giving negative side effects. Camptothecin (CPT) is a natural alkaloid of a 
plant, Camptotheca acuminata, and has anticancer property with topoisomerase 
inhibitory activity [135]. Irinotecan or CPT-11 (94) is an alkaloid derivative 
of camptothecin and used as anticancer drug (Figure 21). Irinotecan (94) is a 
prodrug, which is transformed in vivo through hydrolysis by carboxylesterase 
enzymes, giving an active metabolite, SN-38 (95) (Figure 21) [136]. Uridine 
diphosphate-glucuronosyltransferase enzymes catalyze the conversion of SN-38 
(95) to a glucuronidated derivative, SN-38G (96) (Figure 21). The metabolite 
SN-38G (96) is inactive for cancer cells and is excreted into the gastrointestinal 
tract [137], where the gut bacteria use β-glucuronidase enzymes to convert 
SN-38G (96) to SN-38 (95) that causes severe diarrhea in patients (Figure 21) 
[138]. This side effect reflects the significant negative effects of gut bacteria in 
the drug metabolism. However, the use of antibiotics, e.g., levofloxacin, to reduce 
Figure 20. 
Bioconversion of xanthohumol (88) to isoxanthohumol (89), 8-prenylnaringenin (90), 
O-desmethylxanthohumol (91), desmethyl-α,β-dihydroxanthohumol (92), and α,β-dihydroxanthohumol (93) 
by human gut bacteria.
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the population of gut bacteria in the gastrointestinal tract is not recommended 
for patients because it has many consequent problems [139]. Gut microbiotas are 
important for a healthy gastrointestinal tract, and they play many essential roles in 
dietary metabolisms [140, 141]; the treatment of cancer should not give any effects 
to gut microorganisms. Therefore, the use of antibiotic drugs, which affect gut 
microbiota, is not recommended. To reduce the diarrhea side effect without affect-
ing gut microorganisms, a research led by Redinbo employed appropriate inhibitors 
of gut bacterial β-glucuronidase enzymes, in order to prevent the formation of 
SN-38 (95), a causative agent of severe diarrhea in patients [142]. Certain inhibi-
tors exhibited β-glucuronidase inhibitory activity in living bacterial cells without 
disturbing the growth of gut bacteria or giving any damaging effects toward mam-
malian cells. Indeed, in a mouse model, mice treated with both irinotecan (94) and 
a β-glucuronidase inhibitor had less diarrhea and bloody diarrhea than the group 
receiving only the drug irinotecan (94). Therefore, the inhibition of microbial 
β-glucuronidases could prevent the production of toxic metabolite, SN-38 (95), 
during the treatment of anticancer drug, irinotecan (94) [142]. This is an example 
Figure 21. 
Structures of irinotecan or CPT-11 (94) and its metabolites, SN-38 (95) and SN-38G (96), and the 
bioconversion of SN-38G (96) to SN-38 (95) by gut bacterial β-glucuronidase.
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of a toxic drug metabolite produced by the activity of gut microbiome, and the 
manipulation of the enzyme activity of gut bacteria could be done by using another 
drug (an inhibitor of bacterial enzyme).
Some natural products can alter the composition of gut microbiome, and 
changes in gut microbiome lead to the drug-induced negative side effects on certain 
treatments. Paclitaxel or Taxol (97) is an anticancer drug for the treatment of many 
types of cancers (Figure 22), and it is a natural product isolated from a Pacific yew 
tree, Taxus brevifolia. In a mouse model, paclitaxel (97) chemotherapy could change 
the composition of gut bacterial community and induce negative effects such as 
sickness behaviors, i.e., fatigue and anorexia, increased central and peripheral 
inflammation, and impaired cognitive performance [143]. These negative effects 
might be associated with changes in gut bacteria because paclitaxel (97) therapy 
decreased the abundance of gut bacteria including Lachnospiraceae bacteria and 
butyrate-producing bacteria, which are necessary for human gut health [143]. 
Therefore, the negative effects of cancer chemotherapy may be attenuated by 
improving the composition of gut microbiota, for example, the use of prebiotic 
or probiotic supplements, which has become one of the emerging approaches 
to change the microbiota composition, thus improving therapeutic outcome for 
patients treated with anticancer drugs [144].
Antibiotic drugs have significant effects on the metabolism of drugs and phyto-
chemicals because they could suppress enzymatic activities of gut microbiome [92]. 
Therefore, if patients are treated with an antibiotic drug together with another drug, 
there are possible drug–drug interactions due to changes of gut microbiota caused 
by antibiotic drugs. Lovastatin (98) (Figure 23), a natural polyketide isolated 
from the fungus Aspergillus terreus [145], is a cholesterol-lowering drug, which is a 
member of the statin family. Lovastatin (98) has the interactions with antibiotics 
through the mediation of gut microbiome [146]. Incubation of lovastatin (98) with 
human and rat fecalase revealed the biotransformation of this drug by gut micro-
biota, giving four major metabolites including demethylbutyryl-lovastatin (99), 
hydroxylated-lovastatin (100), hydroxy acid-lovastatin (101), and OH-hydroxy 
acid-lovastatin (102) (Figure 23) [146]. These four metabolites were also found 
in rat plasma, and they might be from gut microbiota-mediated metabolism of the 
drug lovastatin (98). Among the drug metabolites, hydroxy acid-lovastatin (101) 
is the active form, which could effectively inhibit 3-hydroxy-3-methylglutaryl 
coenzyme-A reductase, the target enzyme of this cholesterol-lowering drug [147].
Figure 22. 
Structure of an anticancer drug paclitaxel or Taxol (97).
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In an animal model, rats with an oral administration of lovastatin (98) were 
compared with those treated with lovastatin (98) and antibiotics; the pharmacoki-
netic study revealed that the levels of the active metabolite hydroxy acid-lovastatin 
(101) in antibiotic-treated rats were lower than that without antibiotics. This result 
indicates that antibiotic drugs reduce the biotransformation of the drug lovastatin 
(98) to its active form, hydroxy acid-lovastatin (101), because antibiotics affect 
gut microbiome. The in vivo metabolism of lovastatin (98) to its active form, 
hydroxy acid-lovastatin (101), is important for the therapeutic efficacy of this drug; 
therefore antibiotic intake of patients treated with lovastatin (98) would lead to 
the decrease of the active form, hydroxy acid-lovastatin (101), thus decreasing its 
therapeutic effects [146]. This study clearly demonstrates the drug–drug interac-
tion mediated by changes of gut microbiome.
4. Conclusions
Intriguingly, gut microbiome is very important for human health and diseases, 
and it is therefore recognized as an “organ” or a “tissue” in the human body. Gut 
microorganisms have much more genes encoding enzymes than those of human 
Figure 23. 
Structures of major metabolites of lovastatin (98) including demethylbutyryl-lovastatin (99),  
hydroxylated-lovastatin (100), hydroxy acid-lovastatin (101), and OH-hydroxy acid-lovastatin (102).
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genome; therefore, enzymes of these microbes are involved in many biochemical 
processes, i.e., metabolism of xenobiotics (compounds not produced in human host, 
e.g., drugs and pollutants) and dietary sources. Metabolites produced by gut micro-
biome play significant roles in human health and diseases; these metabolites include 
short-chain fatty acids such as butyrate (11), as well as other metabolites, e.g., 
nicotinamide (12), 5-aminovaleric acid (14), and taurine (15) (see Section 2). Since 
gut microbiome and its metabolites substantially contribute to human health and 
diseases, a therapy by intervention strategies using gut microbiota can potentially be 
useful for some diseases, for example, metabolic disorders, cardiovascular disease, 
food allergy, and neurological disorders. Supplementation with probiotics or certain 
gut bacteria, as well as their metabolites, may be a new therapeutic method in the 
future. Fecal microbiota transplantation, e.g., transferring gut bacteria from healthy 
individuals into patients, is a challenging research study in the near future.
Gut microbiome can metabolite commonly used drugs and natural products. 
Drug metabolism by gut microorganisms decreases the levels of drugs in serum, 
thus disturbing the drug pharmacokinetics, which can lead to alteration of thera-
peutic efficiency. Moreover, metabolites produced by the drug metabolism of 
gut microbiome contribute considerably to the drug efficacy. For example, the 
levels of the drug L-dopa (56) are substantially reduced by the metabolic activ-
ity of gut microbiome, and this results in the requirement of higher doses for the 
Parkinson’s patients with gut microbiome that has high metabolic activity toward 
the drug L-dopa (56) (see Section 3.1). This example well demonstrates the role 
of gut microorganisms on treatment outcomes of the commonly used drugs. Gut 
microbiome could improve many drug therapies, for example, cancer immuno-
therapy targeting CTLA-4 blockade and immune checkpoint inhibitor via the 
PD-1/PD-L1 pathway. Moreover, the metabolism of gut microbiome improves drug 
efficacy because it assists the bioconversion of some drugs into their active forms, 
for example, a biotransformation of lovastatin (98) to its active form, hydroxy 
acid-lovastatin (101), and a bioconversion of aspirin (70) to salicylic acid (71) that 
actively reduces pain. Interestingly, gut microbiome involves in a biotransformation 
of an alkaloid natural product berberine (78) to an absorbable form, dihydrober-
berine (80), which is absorbed at the intestine system (see Section 3.2). This result 
demonstrates that gut microbiome facilitates drug delivery of berberine (78) that 
has poor solubility by a biotransformation to an absorbable form, dihydroberberine 
(80), which is in turn converted to its active form berberine (78) in the human 
body. Since gut microbiome plays many important roles in drugs and natural 
products, the metabolism of natural products and drug candidates by gut microbi-
ome should therefore be studied, and it should be a part of the drug development 
process. Gut microbiome can potentially play a crucial role for the improvement of 
drug safety and efficacy.
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